An open-label, two period, fixed sequence study of healthy subjects to assess the effect of repeat oral dosing of [Rifampin] on the pharmacokinetics of a single oral dose of [GW679769] (casopitant).
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2017
At a glance
- Drugs Casopitant (Primary) ; Rifampicin
- Indications Anxiety disorders; Chemotherapy-induced nausea and vomiting; Depressive disorders; Postoperative nausea and vomiting; Tuberculosis
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 26 Jan 2007 New trial record.